Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | OTHER |
| Weill Medical College of Cornell University | OTHER |
| Florida International University | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a randomized, unblinded study comparing standard vs. same-day treatment for patients with TB symptoms (cough, fever, night sweats, or weight loss) at HIV diagnosis. Six hundred patients will be randomized in a 1:1 ratio to the standard group or the same-day treatment group. All study activities will take place at the GHESKIO Centers in Port-au-Prince, Haiti. The study population includes HIV-infected men and women ≥18 years of age who are ART-naïve, and who present with symptoms of TB (cough, fever, nights sweats, or weight loss) at HIV diagnosis.
This study is a randomized trial that will compare outcomes with standard and same-day treatment among patients with TB symptoms at HIV diagnosis. The standard group will receive same-day chest x-ray as well as Xpert Ultra testing with a spot specimen (with 48-hour turn-around-time). Participants will return for Xpert Ultra results and early morning sputum testing on Day 2. TB treatment will be provided on the day of diagnosis (Day 0 for those with high clinical and radiographic suspicion of TB, and Day 2 for those diagnosed by spot Xpert Ultra). Standard group participants who are not diagnosed with TB will be tested and treated for other opportunistic infections (OIs), as clinically indicated, and will initiate ART on Day 7. The same-day group will receive Xpert Ultra testing (with same-day results) and chest x-ray with same-day ART or TB treatment (on Day 0) based on test results. They will also be tested and treated for other OIs as clinically indicated. They will provide early morning sputum for repeat testing on Day 1. Both groups will receive Xpert Ultra testing on both spot and early morning specimens, with liquid culture on both specimens as the diagnostic gold standard; those with TB will start ART according to WHO guidelines.
Three specific aims are proposed:
Aim 1: To compare the proportion of participants in each group who are alive and in care with undetectable viral load (<200 copies/ml) at 48 weeks after HIV testing. Hypothesis: The proportion of participants retained in care with undetectable viral load will be 51% in the standard and 65% in the same-day group.
Aim 2: To compare mortality in each group at 48 weeks after HIV testing. Hypothesis: Mortality will be 10% in the standard group and 4% in the same-day group.
Aim 3: To conduct a comparison of cost and cost-effectiveness of standard and same-day care, where cost is measured by the mean treatment cost and effectiveness is measured by being alive and in care with plasma HIV-1 RNA level <200 copies/ml at 48 weeks after HIV testing. Hypothesis: Same-day treatment will cost less per patient retained in care with undetectable viral load.
Aim 4: To determine the rates of ART and TB treatment initiation, TB diagnosis after ART initiation, IRIS, adverse events, and adherence in both groups, and to evaluate the sensitivity, specificity, and predictive values of single tests and different testing combinations compared to liquid mycobacterial culture results.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard Group | Active Comparator | On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 7, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens. |
|
| Same-Day Treatment Group | Experimental | On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Same-Day Treatment | Other | Treatment with ART or TB medication on day of HIV diagnosis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Retention in care with viral suppression | Proportion of participants who are in care with HIV-1 RNA <200 copies/ml | 48 weeks after HIV testing |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | All-cause mortality | 48 weeks after HIV testing |
| Mean treatment cost per participant | Mean treatment cost per participant |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Serena P Koenig, MD | Brigham and Women's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GHESKIO | Port-au-Prince | Haiti |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37294843 | Derived | Dorvil N, Rivera VR, Riviere C, Berman R, Severe P, Bang H, Lavoile K, Devieux JG, Faustin M, Saintyl G, Mendicuti MD, Pierre S, Apollon A, Dumond E, Forestal GPL, Rouzier V, Marcelin A, McNairy ML, Walsh KF, Dupnik K, Reif LK, Byrne AL, Bousleiman S, Orvis E, Joseph P, Cremieux PY, Pape JW, Koenig SP. Same-day testing with initiation of antiretroviral therapy or tuberculosis treatment versus standard care for persons presenting with tuberculosis symptoms at HIV diagnosis: A randomized open-label trial from Haiti. PLoS Med. 2023 Jun 9;20(6):e1004246. doi: 10.1371/journal.pmed.1004246. eCollection 2023 Jun. | |
| 33616229 |
Not provided
Not provided
When the study has been completed, anonymized data will be made publicly available, which will permit replication of reported outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D014376 | Tuberculosis |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
| University of California, Davis |
| OTHER |
| Analysis Group, Inc. | INDUSTRY |
Patients will be randomized in a 1:1 ratio to standard or same-day treatment
Not provided
Not provided
Not provided
Not provided
| Standard treatment | Other | Standard treatment |
|
| 48 weeks after HIV testing |
| Viral suppression | Proportion of participants with HIV-1 RNA <50 copies/ml and <1000 copies/ml | 48 weeks after HIV testing |
| Adherence by medication possession ratio | Proportion of participants with 48-week adherence to ART of at least 90% by pharmacy refill records | 48 weeks after HIV testing |
| Adherence by 3-day self-report | Proportion of participants with perfect (100%) adherence as measured by 3-day self-report at 48 weeks after HIV testing | 48 weeks after HIV testing |
| Treatment failure | Proportion of participants meeting WHO criteria for ART failure and proportion initiating second-line ART during the study period | 48 weeks |
| TB testing characteristics | Sensitivity, specificity, predictive values, and likelihood ratios of spot and early morning Xpert Ultra results and chest x-ray, as single and as combined tests, with liquid culture as gold standard | These diagnostic tests will be conducted during the first week of study enrollment |
| Time in clinic | Median time spent in clinic during first day and month of the study | First study day and first study month |
| Coping with HIV diagnosis | Scores on the COPE survey | 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing |
| Connectedness to Treatment Setting | Scores on the Connectedness to Treatment Setting Scale | 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing |
| TB diagnosis after ART initiation | Diagnosis of culture-positive TB after ART initiation (BACTEC MGIT 960, Becton Dickinson) | 48-week study period |
| Incidence of immune reconstitution inflammatory syndrome (IRIS) | Incidence of paradoxical or unmasking IRIS | 48-week study period |
| Adverse events | New Division of AIDS Grade 3 or Grade 4 signs, symptoms, or laboratory abnormalities that are at least a one-grade increase from baseline | 48-week study period |
| Measure of hope and optimism | Scores on the State Hope Scale | 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing |
| Patient satisfaction | Scores on the HRSA Patient Satisfaction Survey | 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing |
| Time to death | Days to death | 48-week study period |
| Last missed dose of medication | Proportion of participants who report last missed dose of ART was at least 2 weeks ago | 2 Weeks, 12 Weeks, 24 Weeks, 48 Weeks |
| Derived |
| Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, Ochodo EA, Haraka F, Zwerling AA, Pai M, Steingart KR, Horne DJ. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD009593. doi: 10.1002/14651858.CD009593.pub5. |
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |